U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    CD109 CD109 molecule [ Homo sapiens (human) ]

    Gene ID: 135228, updated on 5-Mar-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    H3K27 acetylation activated-CD109 evokes 5-fluorouracil resistance in gastric cancer via the JNK/MAPK signaling pathway.

    H3K27 acetylation activated-CD109 evokes 5-fluorouracil resistance in gastric cancer via the JNK/MAPK signaling pathway.
    Zhou F, Wang L, Ge H, Zhang D, Wang W.

    11/22/2023
    CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.

    CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
    Kim JS, Shin MJ, Lee SY, Kim DK, Choi KU, Suh DS, Kim D, Kim JH., Free PMC Article

    07/7/2023
    CD109-regulated mechanical properties of endothelial cells.

    CD109-regulated mechanical properties of endothelial cells.
    Starodubtseva MN, Liu J, Nadyrov EA, Shkliarava NM, Sadouskaya AU, Starodubtsev IE, Achinovich SL, Meng X, Zinovkin DA, Pranjol MZI.

    06/22/2023
    Significance of expression of CD109 in osteosarcoma and its involvement in tumor progression via BMP signaling.

    Significance of expression of CD109 in osteosarcoma and its involvement in tumor progression via BMP signaling.
    Mori N, Esaki N, Shimoyama Y, Shiraki Y, Asai N, Sakai T, Nishida Y, Takahashi M, Enomoto A, Mii S.

    05/30/2023
    Placental and plasma early predictive biomarkers for gestational diabetes mellitus.

    Placental and plasma early predictive biomarkers for gestational diabetes mellitus.
    Wei Y, He A, Huang Z, Liu J, Li R.

    07/23/2022
    CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer.

    CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer.
    Adachi K, Sakurai Y, Ichinoe M, Tadehara M, Tamaki A, Kesen Y, Kato T, Mii S, Enomoto A, Takahashi M, Koizumi W, Murakumo Y.

    05/7/2022
    The Significance of CD109 Expression in Oropharyngeal Squamous Cell Carcinoma.

    The Significance of CD109 Expression in Oropharyngeal Squamous Cell Carcinoma.
    Tsutsumi S, Momiyama K, Ichinoe M, Kato T, Mogi S, Miyamoto S, Murakumo Y, Yamashita T.

    04/9/2022
    The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-beta.

    The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-β.
    Tanabe M, Hosokawa K, Nguyen MAT, Nakagawa N, Maruyama K, Tsuji N, Urushihara R, Espinoza L, Elbadry MI, Mohiuddin M, Katagiri T, Ono M, Fujiwara H, Chonabayashi K, Yoshida Y, Yamazaki H, Hirao A, Nakao S.

    03/12/2022
    Single-cell analysis pinpoints distinct populations of cytotoxic CD4(+) T cells and an IL-10(+)CD109(+) TH2 cell population in nasal polyps.

    Single-cell analysis pinpoints distinct populations of cytotoxic CD4(+) T cells and an IL-10(+)CD109(+) T(H)2 cell population in nasal polyps.
    Ma J, Tibbitt CA, Georén SK, Christian M, Murrell B, Cardell LO, Bachert C, Coquet JM.

    03/5/2022
    CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity.

    CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity.
    Filppu P, Tanjore Ramanathan J, Granberg KJ, Gucciardo E, Haapasalo H, Lehti K, Nykter M, Le Joncour V, Laakkonen P., Free PMC Article

    02/19/2022
    Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.

    Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma.
    Hagiwara S, Sasaki E, Hasegawa Y, Suzuki H, Nishikawa D, Beppu S, Terada H, Sawabe M, Takahashi M, Hanai N., Free PMC Article

    08/7/2021
    Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling.

    Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling.
    Lee KY, Kuo TC, Chou CM, Hsu WJ, Lee WC, Dai JZ, Wu SM, Lin CW., Free PMC Article

    07/17/2021
    CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.

    CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.
    Mo XT, Leung TH, Tang HW, Siu MK, Wan PK, Chan KK, Cheung AN, Ngan HY., Free PMC Article

    04/3/2021
    CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells.

    CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells.
    Hatsuzawa Y, Yamaguchi K, Takanashi T, Sato I, Tamai K, Mochizuki M, Iwai W, Wakui Y, Abue M, Yamamoto K, Yasuda J, Mizuma M, Unno M, Sugamura K.

    02/27/2021
    CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro.

    CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro.
    Zhou S, da Silva SD, Siegel PM, Philip A., Free PMC Article

    10/31/2020
    Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy.

    Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy.
    Bastola S, Pavlyukov MS, Yamashita D, Ghosh S, Cho H, Kagaya N, Zhang Z, Minata M, Lee Y, Sadahiro H, Yamaguchi S, Komarova S, Yang E, Markert J, Nabors LB, Bhat K, Lee J, Chen Q, Crossman DK, Shin-Ya K, Nam DH, Nakano I., Free PMC Article

    10/3/2020
    Expression of CD109 is correlated with the invasive and metastatic capacities of lung adenocarcinoma cells. CD109 is upregulated in tumorous tissues, and CD109 overexpression is associated with tumor progression, distant metastasis, and poor prognosis in patients. Inhibition of CD109 decreases EGFR phosphorylation, diminishes EGF-elicited activation of AKT/mTOR, and sensitizes tumor cells to an EGFR inhibitor.

    Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
    Lee KY, Shueng PW, Chou CM, Lin BX, Lin MH, Kuo DY, Tsai IL, Wu SM, Lin CW., Free PMC Article

    06/6/2020
    findings show elevated CD109 protein expression in esophageal squamous cell carcinoma (ESCC); CD109 expression is restricted in squamous cells of ESCCs

    Elevated Expression of CD109 in Esophageal Squamous Cell Carcinoma.
    Dong F, Liu F, Yan S, Liu X, Jiang Z, Liu J.

    09/7/2019
    GRP78 binds to and acts in concert with a glycosylphosphatidylinositol-anchored protein, CD109, in blocking TGF-beta signaling by promoting the routing of the TGF-beta receptor to the caveolae, thereby disrupting its binding to and activation of Smad2.

    Endoplasmic reticulum stress activates SRC, relocating chaperones to the cell surface where GRP78/CD109 blocks TGF-β signaling.
    Tsai YL, Ha DP, Zhao H, Carlos AJ, Wei S, Pun TK, Wu K, Zandi E, Kelly K, Lee AS., Free PMC Article

    08/18/2018
    CD109 knockdown upregulated IL-8 expression through activation of TGF-beta/Akt/NF-kappaB pathway in human umbilical vein endothelial cells

    Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma.
    Ye BG, Sun HC, Zhu XD, Chai ZT, Zhang YY, Ao JY, Cai H, Ma DN, Wang CH, Qin CD, Gao DM, Tang ZY., Free PMC Article

    12/23/2017
    High expression of CD109 in brain tumor stem cells is involved in glioma progression.

    Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
    Shiraki Y, Mii S, Enomoto A, Momota H, Han YP, Kato T, Ushida K, Kato A, Asai N, Murakumo Y, Aoki K, Suzuki H, Ohka F, Wakabayashi T, Todo T, Ogawa S, Natsume A, Takahashi M.

    12/9/2017
    CD109 is a putative biomarker for identifying a high-risk group among DLBCL patients.

    CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.
    Yokoyama M, Ichinoe M, Okina S, Sakurai Y, Nakada N, Yanagisawa N, Jiang SX, Numata Y, Umezawa A, Miyazaki K, Higashihara M, Murakumo Y.

    06/10/2017
    The most common HPA genotypes among Saudis were HPA-1 a + b- (75%), HPA-2 a + b- (62%), HPA-3 a + b- (51.5%), HPA-4 a + b- (99%), HPA-5 a + b- (76.5%), HPA-6 a + b- (100%) and HPA-15 a + b + (50%). The prevalent allele among the HPA systems was (a), except in the HPA-15 system where the (b) allele was found in 52% of the subjects.

    Gene frequency of human platelet alloantigens-1 to -6 and -15 in Saudi blood donors.
    Al-Ouda SK, Al-Banyan AA, Abdel Gader AG, Bayoumy NM, Al-Gahtani FH.

    03/25/2017
    Expression levels of CD109 was reduced significantly in psoriasis. Lower expression of CD109 and TGF-beta RI was highly correlated with higher expression of Smad7 and Ki67, suggesting that CD109 may induce the pathogenesis of psoriasis through Smad7-mediated degradation of TGF-beta RI.

    Association of down-regulation of CD109 expression with up-expression of Smad7 in pathogenesis of psoriasis.
    Liu XX, Feng AP, He YM, Li Y, Wu Y, Lian X, Hu F, Li JW, Tu YT, Chen SJ.

    12/31/2016
    sCD109 can bind TGF-beta, inhibit TGF-beta binding to its receptors and decrease TGF-beta signalling and TGF-beta-induced cellular responses.

    Soluble CD109 binds TGF-β and antagonizes TGF-β signalling and responses.
    Li C, Hancock MA, Sehgal P, Zhou S, Reinhardt DP, Philip A.

    08/20/2016
    firstprevious page of 3 nextlast